Related Experiment Videos

Atorvastatin improves endothelial function and cardiac performance in patients with dilated cardiomyopathy: the role

Miao Liu1, Fang Wang, Yanrong Wang

  • 1Department of paediatrics, Wuhan Union Hospital, Huazhong University of Science and Technology, Wuhan, 430022, China.

Cardiovascular Drugs and Therapy
|July 29, 2009
PubMed

Insights

Atorvastatin treatment in patients with idiopathic dilated cardiomyopathy (IDCM) significantly improved cardiac function and exercise capacity. The drug reduced inflammation and improved endothelial function, offering a potential therapeutic benefit for IDCM patients.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Statins are known to impact cardiac disease prognosis.
  • Pleiotropic effects of statins in cardiac patients are increasingly recognized.

Purpose of the Study:

  • To investigate the effects of atorvastatin on inflammation, endothelial function, cardiac performance, and exercise tolerance in patients with idiopathic dilated cardiomyopathy (IDCM).

Main Methods:

  • Sixty-four IDCM patients were randomized into atorvastatin (10 mg/d) and placebo groups.
  • Evaluated biomarkers: soluble intercellular adhesion molecule-1 (sICAM-1), Von Willebrand factor (vWF), C-reactive protein (CRP).
  • Assessed endothelial function (Flow-mediated dilatation - FMD), cardiac performance (left ventricular ejection fraction - LVEF), and exercise tolerance (6-min walk test - 6MWT) before and after 12 weeks.

Main Results:

  • Atorvastatin significantly increased LVEF and 6MWT distance compared to placebo (P < 0.05).
  • Treatment reduced sICAM-1, CRP, and vWF levels, and increased FMD significantly in the atorvastatin group.
  • Baseline sICAM-1 correlated positively with CRP and vWF; FMD correlated inversely with sICAM-1 and vWF, and positively with LVEF and 6MWT.

Conclusions:

  • Twelve weeks of atorvastatin therapy improved LVEF, 6MWT outcomes, and endothelial function in IDCM patients.
  • Mechanisms may involve the inhibition of inflammation and alleviation of endothelial damage/dysfunction.
  • Atorvastatin shows promise for improving cardiac function and exercise tolerance in IDCM.
Abstract

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...